PolyPeptide Accepts CHF1.46 Billion All-cash Takeover Offer from Samsung Biologics

11:16 PM EDT, 07/19/2026 (MT Newswires) -- PolyPeptide Group (PPGN.SW) accepted an all-cash public tender offer from Samsung Biologics for an equity valuation of 1.46 billion francs. Samsung Biologics is offering 44.31 francs per share for the Swiss contract drugmaker, according to a Monday release. The offer price reflects a premium of 40% to the last undisturbed share price as of April 10. PolyPeptide's board intends to unanimously recommend that shareholders accept the offer following a comprehensive strategic review. Its largest shareholder, Draupnir Holding, has committed to tender its entire 55.65% stake into the offer. South Korea-listed Samsung Biologics, a contract development and manufacturing organization, said in a same-day release that the deal is expected to be completed by the end of 2026, subject to customary conditions.